Pasireotide LAR and octreotide LAR maintain inhibition of GH and IGF1 in patients with acromegaly: 12-month extension phase of a randomized, double-blind, multicenter, phase III study
Keyword(s):
Keyword(s):
2017 ◽
Vol 39
(10)
◽
pp. 2049-2060
◽
Keyword(s):
Keyword(s):
2011 ◽
Vol 29
(15_suppl)
◽
pp. TPS152-TPS152
◽
Keyword(s):
Keyword(s):
2016 ◽
Vol 38
(10)
◽
pp. 2171-2184
◽
Keyword(s):